 |
Clinical Study
An IRB-approved clinical trial featuring randomization, double-blind,
placebo-controlled, crossover group design showed statistically
significant differences over placebo for 17 common
hangover symptoms including headaches,
nausea and fatigue.
According to the trial's executive summary, "The efficacy of the
product 'Chaser' appears to be proven based on the clinical trial. All of
the major symptoms associated with moderate alcohol consumption
were improved while on the product." The report goes on to say,
"There appears to be no drawbacks to this product with respect to
safety as determined by this trial. Furthermore, the active ingredients
have a long medical history of use and are generally recognized as
safe (GRAS) by the FDA."
At the conclusion of the test, 83 percent of the subjects said they
would "highly recommend" or "recommend" Chaser.
On average, subjects reported improvement in all 17 categories while
taking Chaser.
Selected average improvements are listed below.
Hangover
Symptom
|
% Improvement
over Placebo |
|
Headache |
70.4 |
|
Bloating |
70.0 |
|
Sweating |
67.4 |
|
Dizziness |
63.2 |
|
Feeling “Hungover” |
54.5 |
|
Dry Mouth |
45.0 |
|
Nausea |
36.4 |
|
Fatigue |
29.3 |
|
|
|
 |
